FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2732250263> ?p ?o ?g. }

• W2732250263 endingPage "271" @default.
• W2732250263 startingPage "265" @default.
• W2732250263 abstract "Urinary tract infections (UTI) are among the most common infections in pediatric patients. The main etiopathogenic agent is Escherichia coli. The purpose of this study was to determine the antimicrobial resistance pattern of E. coli in pediatric patients and to understand their main clinical and laboratory manifestations. Fifty-nine patients were included in the study and classified into two groups: hospitalization (H) and external consultation (EC). Every patient presented urine cultures with the isolation of E. coli that included an antibiogram. Clinical signs and symptoms, urinalysis, complete blood count (CBC) and serum inflammatory markers were analyzed. The most common clinical manifestations were fever (H: 76.5%; EC: 88%), vomiting (H: 32.4%; EC: 32%), hyporexia (H: 20.6%; EC: 16%), abdominal pain (H: 20.6%: EC: 28%), and dysuria (H: 14.7%; EC: 32%). Ten patients (16.95%) presented UTI for extended spectrum beta-lactamase (ESBL) E. coli. Ampicillin, nalidixic acid, and trimethoprim-sulfamethoxazole showed a higher resistance rate, being ampicillin the most significant (H: 88.2%; EC: 92%). Leukocyturia, bacteriuria and urine nitrites were frequent alterations in urinalysis (H: 52.9%; EC: 92%). In ESBL E. coli patients, a positive correlation was found between leukocytes in CBC and C-reactive protein (r = 0.9, p < 0.01). Diarrhea and foul-smelling urine were associated with E. coli resistance. The presence of leukocytes, bacteria, nitrites and the Gram stain are the most common indicators. Nitrofurantoin and phosphomycin are good therapeutic options. However, an antibiogram must be conducted to determine the best therapeutic agent. Las infecciones de tracto urinario (ITU) se encuentran entre las más frecuentes en pediatría, siendo Escherichia coli el principal agente etiopatogénico. El objetivo de este estudio fue determinar el patrón de resistencia antimicrobiana de E. coli en pacientes pediátricos y conocer sus principales manifestaciones clínicas y de laboratorio. Se incluyeron en el estudio 59 pacientes en dos grupos: hospitalización (H) y consulta externa (CE). En cada uno se realizó un urocultivo y un antibiograma con aislamiento de E. coli. Se analizaron signos y síntomas, uroanálisis, hemograma y marcadores séricos de inflamación. Las manifestaciones clínicas más frecuentes fueron fiebre (H: 76.5%; CE: 88%), vómito (H: 32.4%; CE: 32%), hiporexia (H: 20.6%; CE: 16%), dolor abdominal (H: 20.6%: CE: 28%) y disuria (H: 14.7%; CE: 32%). Diez pacientes (16.95%) presentaron ITU por E. coli beta-lactamasa de espectro extendido (BLEE). La ampicilina, ácido nalidíxico y trimetroprim con sulfametoxazol mostraron alta resistencia, siendo ampicilina la más significativa (H: 88.2%, CE: 92%). Leucocituria, bacteriuria y nitritos en orina fueron frecuentes en el uroanálisis. En pacientes con E. coli BLEE se encontró una correlación positiva entre los leucocitos y la proteína C reactiva (r = 0.9, p < 0.01). La diarrea y el mal olor en la orina se asociaron con resistencia de E. coli. La leucocituria, la bacteriuria, los nitritos y la tinción Gram son los indicadores más frecuentes de ITU. La nitrofurantoina y fosfomicina son buenas opciones terapéuticas. Sin embargo, debe realizarse un antibiograma para determinar el mejor tratamiento." @default.
• W2732250263 created "2017-07-14" @default.
• W2732250263 creator A5004807890 @default.
• W2732250263 creator A5035802303 @default.
• W2732250263 creator A5038534757 @default.
• W2732250263 creator A5057801673 @default.
• W2732250263 creator A5060889495 @default.
• W2732250263 creator A5061911444 @default.
• W2732250263 creator A5062093435 @default.
• W2732250263 date "2017-07-01" @default.
• W2732250263 modified "2023-09-26" @default.
• W2732250263 title "Clinical characterization and antimicrobial resistance of Escherichia coli in pediatric patients with urinary tract infection at a third level hospital of Quito, Ecuador" @default.
• W2732250263 cites W1585063521 @default.
• W2732250263 cites W1970540449 @default.
• W2732250263 cites W2001628017 @default.
• W2732250263 cites W2019046778 @default.
• W2732250263 cites W2042201973 @default.
• W2732250263 cites W2070275406 @default.
• W2732250263 cites W2087579452 @default.
• W2732250263 cites W2095679832 @default.
• W2732250263 cites W2095918352 @default.
• W2732250263 cites W2108044415 @default.
• W2732250263 cites W2112900304 @default.
• W2732250263 cites W2113565511 @default.
• W2732250263 cites W2134960088 @default.
• W2732250263 cites W2212803607 @default.
• W2732250263 cites W2241838063 @default.
• W2732250263 cites W2297704909 @default.
• W2732250263 cites W2302072061 @default.
• W2732250263 cites W2302483558 @default.
• W2732250263 cites W3082107673 @default.
• W2732250263 cites W4364863714 @default.
• W2732250263 doi "https://doi.org/10.1016/j.bmhimx.2017.02.004" @default.
• W2732250263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29382515" @default.
• W2732250263 hasPublicationYear "2017" @default.
• W2732250263 type Work @default.
• W2732250263 sameAs 2732250263 @default.
• W2732250263 citedByCount "8" @default.
• W2732250263 countsByYear W27322502632019 @default.
• W2732250263 countsByYear W27322502632021 @default.
• W2732250263 countsByYear W27322502632022 @default.
• W2732250263 countsByYear W27322502632023 @default.
• W2732250263 crossrefType "journal-article" @default.
• W2732250263 hasAuthorship W2732250263A5004807890 @default.
• W2732250263 hasAuthorship W2732250263A5035802303 @default.
• W2732250263 hasAuthorship W2732250263A5038534757 @default.
• W2732250263 hasAuthorship W2732250263A5057801673 @default.
• W2732250263 hasAuthorship W2732250263A5060889495 @default.
• W2732250263 hasAuthorship W2732250263A5061911444 @default.
• W2732250263 hasAuthorship W2732250263A5062093435 @default.
• W2732250263 hasBestOaLocation W27322502631 @default.
• W2732250263 hasConcept C104317684 @default.
• W2732250263 hasConcept C126322002 @default.
• W2732250263 hasConcept C2775876089 @default.
• W2732250263 hasConcept C2775886723 @default.
• W2732250263 hasConcept C2776021129 @default.
• W2732250263 hasConcept C2776216170 @default.
• W2732250263 hasConcept C2776845205 @default.
• W2732250263 hasConcept C2777629877 @default.
• W2732250263 hasConcept C2777894859 @default.
• W2732250263 hasConcept C2778910516 @default.
• W2732250263 hasConcept C2779225474 @default.
• W2732250263 hasConcept C2779425571 @default.
• W2732250263 hasConcept C2780026642 @default.
• W2732250263 hasConcept C2780728791 @default.
• W2732250263 hasConcept C2780852908 @default.
• W2732250263 hasConcept C2781276175 @default.
• W2732250263 hasConcept C4937899 @default.
• W2732250263 hasConcept C501593827 @default.
• W2732250263 hasConcept C547475151 @default.
• W2732250263 hasConcept C55493867 @default.
• W2732250263 hasConcept C71924100 @default.
• W2732250263 hasConcept C77411442 @default.
• W2732250263 hasConcept C86803240 @default.
• W2732250263 hasConcept C89423630 @default.
• W2732250263 hasConcept C90924648 @default.
• W2732250263 hasConcept C94665300 @default.
• W2732250263 hasConceptScore W2732250263C104317684 @default.
• W2732250263 hasConceptScore W2732250263C126322002 @default.
• W2732250263 hasConceptScore W2732250263C2775876089 @default.
• W2732250263 hasConceptScore W2732250263C2775886723 @default.
• W2732250263 hasConceptScore W2732250263C2776021129 @default.
• W2732250263 hasConceptScore W2732250263C2776216170 @default.
• W2732250263 hasConceptScore W2732250263C2776845205 @default.
• W2732250263 hasConceptScore W2732250263C2777629877 @default.
• W2732250263 hasConceptScore W2732250263C2777894859 @default.
• W2732250263 hasConceptScore W2732250263C2778910516 @default.
• W2732250263 hasConceptScore W2732250263C2779225474 @default.
• W2732250263 hasConceptScore W2732250263C2779425571 @default.
• W2732250263 hasConceptScore W2732250263C2780026642 @default.
• W2732250263 hasConceptScore W2732250263C2780728791 @default.
• W2732250263 hasConceptScore W2732250263C2780852908 @default.
• W2732250263 hasConceptScore W2732250263C2781276175 @default.
• W2732250263 hasConceptScore W2732250263C4937899 @default.
• W2732250263 hasConceptScore W2732250263C501593827 @default.
• W2732250263 hasConceptScore W2732250263C547475151 @default.
• W2732250263 hasConceptScore W2732250263C55493867 @default.
• W2732250263 hasConceptScore W2732250263C71924100 @default.

• next